Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III cross-over non-inferiority trial of generic latanoprost + timolol vs Xalacom in ocular hypertension or primary open angle glaucoma
2021-003387-27Phase 3Completed
- Sponsor
- Polpharma
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of latanoprost + timolol in ocular hypertension and open-angle glaucoma (OAG) (2 arms), sponsored by Polpharma. Started Sep 2021; status: completed.
02
Drugs
latanoprost + timolol
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on 2021-003387-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003387-27.